SYRE — Spyre Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1636282 ·
Last close
$93.81
Market Cap
$8.91B
52W High
$110.64
52W Low
$23.01
ADV30
1,146,491
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -105,719,000 -96,121,000 1,099,728,000 82,727,000 48,193,000
Jun 2026 0 — -81,639,000 -36,200,000 1,173,003,000 162,007,000 71,862,000
Mar 2026 0 — -75,641,000 -69,005,000 763,953,000 97,185,000 93,142,000
Dec 2025 0 — -57,172,000 -62,530,000 777,781,000 85,721,000 62,545,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-249,322,000
Investing CF
$-492,536,000
Financing CF
$759,688,000
CapEx
—
Dividends Paid
—
Buybacks
$-117,000
EPS Diluted TTM
$-2.81
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,328,961,000
Inventory
—
Receivables
—
ST Investments
$989,180,000
EBIT TTM
$-320,171,000
Pretax Income TTM
$-263,856,000
Interest Exp TTM
—
Analysts
15

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -219,562,000 — 777,781,000 62,545,000 715,236,000 -169,252,000
Dec 2024 0 -208,566,000 -208,018,000 608,484,000 90,680,000 517,804,000 -157,410,000
Dec 2023 886,000 -128,564,000 -338,790,000 341,859,000 157,843,000 184,016,000 -99,910,000
Dec 2022 2,329,000 -84,781,000 -83,815,000 71,144,000 20,839,000 50,305,000 -80,144,000
Dec 2021 — — -65,801,000 — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-178,918,000
OpCashFlow TTM
—
Assets (Latest)
$1,173,003,000
Forward EPS
$-3.64

Max Pain — expiry 2027-01-15

max pain strike: $100.00 · spot: $101.46 · call oi: 174 · put oi: 1,034
Expected Move to 2027-01-15: ±$34.90 (34.40%) — implied range $66.56 – $136.36 · ATM straddle on $100.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SMMT Summit Therapeutics Inc. $8.53B $10.67 —
PRAX Praxis Precision Medicines, Inc. $8.53B $305.06 —
TGTX TG THERAPEUTICS, INC. $9.48B $62.71 —
MDGL MADRIGAL PHARMACEUTICALS, INC. $9.80B $421.99 —
RYTM RHYTHM PHARMACEUTICALS, INC. $8.08B $116.61 —

News headlines (Yahoo Finance, 1h cache)

Spyre Therapeutics to Participate in Upcoming Investor Conferences
2026-11-10 13:00 · Yahoo
Spyre Therapeutics (SYRE) Stock Trades At A Premium To Book Value
2026-11-07 21:10 · Yahoo
Spyre Therapeutics Announces Grants of Inducement Awards
2026-11-06 21:05 · Yahoo
Spyre Therapeutics: Q3 Earnings Snapshot
2026-11-03 21:12 · Yahoo
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-03 21:01 · Yahoo
Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
2026-10-24 01:15 · Yahoo
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
2026-10-20 16:48 · Yahoo
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
2026-10-18 13:30 · Yahoo
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
2026-10-08 17:15 · Yahoo
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
2026-10-06 17:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.